Pomegra
N-Power Medicine closed a $32 million Series B led by Labcorp Venture Fund to expand its community oncology network and accelerate adoption of its ProECA clinical trial platform.
- N-Power Medicine closed $32 million in Series B financing on September 1, 2026, with Labcorp Venture Fund as the new lead strategic investor.
- The ProECA platform replaces randomized control arms with prospective external controls generated from routine cancer care, cutting trial size and duration.
- The 40+ site NSCLC network is already in use by biopharma sponsors; colorectal and prostate cancer programs are set to launch before year-end.
Lead
N-Power Medicine, a San Francisco-based clinical research network company, announced on September 1, 2026, the close of a $32 million Series B financing round. Labcorp Venture Fund joined as a new strategic lead, alongside returning investors Merck Global Health Innovation Fund and Innovatus Capital Partners, plus a fourth U.S.-based biotech backer whose name has not been disclosed. Valuation was not made public. The capital will go toward network expansion, deeper pharma partnerships, and continued buildout of the company's ProECA platform across additional tumor types.
What Is N-Power Medicine Actually Selling?
The core product is access to a pre-built, always-on cohort of cancer patients receiving standard-of-care treatment at community oncology clinics. N-Power calls the resulting datasets Prospective External Control Arms - ProECA for short. Drug developers can use these arms to stand in for the placebo or comparator group in a clinical trial, reducing the number of patients who need to be randomized and, in theory, shrinking trial timelines and costs.
The platform generates trial-grade data from routine clinical care rather than purpose-built research settings. That distinction matters to regulators and sponsors: the data is collected prospectively, with patient consent and protocol-level rigor, rather than scraped retrospectively from electronic health records. The first ProECA program, focused on non-small cell lung cancer, is now live across more than 40 community cancer sites embedded within several large U.S. health systems.
Why Is Labcorp Venture Fund Leading This Round?
Labcorp runs one of the largest clinical trial services businesses in the world, touching site selection, patient recruitment, lab testing, and data management. Taking an equity stake in N-Power plugs directly into that infrastructure: community oncology sites generate volume Labcorp can service, and ProECA data creates demand for the biomarker testing Labcorp's labs perform.
For N-Power, the relationship is more than a check. Labcorp's existing site relationships could accelerate network expansion without N-Power having to build every contract from scratch. The prior investor lineup - including Merck Global Health Innovation Fund - signals that biopharma sponsors are betting that community-based external control arms will get regulatory traction. Merck & Co. has already partnered with N-Power to run studies through the platform.
The Clinical Trial Access Problem N-Power Is Targeting
Less than 5% of adult cancer patients in the United States enroll in clinical trials. The structural reason is geographic concentration: historically, the bulk of oncology research runs through large academic medical centers, while roughly 85% of patients receive treatment at community practices. Those patients are invisible to most trial pipelines.
N-Power's network model attempts to close that gap by embedding research infrastructure directly into the community care setting. Sponsors gain access to a more representative patient population; community clinicians gain a path to offering trials without the overhead of running a full investigational site; patients get research access closer to home. Whether that translates into better trial generalizability - or merely faster enrollment - is a question the industry is still working out.
The company acquired Syapse, a precision oncology data platform, in January 2025, which strengthened its real-world data infrastructure and added health system relationships that now underpin parts of the ProECA network.
How Does N-Power Fit Into the Broader Decentralized Trial Movement?
The push toward decentralized and community-embedded trials predates N-Power. But most efforts have focused on remote patient monitoring, telemedicine visits, and home nursing - logistics. N-Power's angle is the control arm itself, which is a structural element of trial design that regulators scrutinize closely.
External control arms are not new. The FDA has accepted them in rare diseases and certain oncology accelerated approvals for years. What N-Power is pitching is a prospective, network-standardized version that may pass muster for broader regulatory use - including in competitive disease settings like NSCLC, where multiple agents are fighting for the same indication. Colorectal and prostate cancer ProECA programs are slated for launch in late 2026, which will test how quickly the model transfers across tumor types with different standard-of-care patterns.
Outlook
N-Power enters this next phase with a validated beachhead in lung cancer, a strategically aligned lead investor with direct operational leverage, and continued backing from a major biopharma sponsor. The near-term execution test is whether the ProECA construct survives regulatory scrutiny in larger, more pivotal trials - a question $32 million and a Labcorp partnership will not answer on their own. Expansion into colorectal and prostate cancer later this year will show how replicable the model is. If the FDA continues warming to prospective external controls, N-Power is well-positioned. If the bar rises, the network value still holds as a recruitment and data asset - just with a lower multiple attached.
